Literature DB >> 12615652

Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment.

Kazuaki Kanai1, Satoshi Kuwabara, Kimihito Arai, Jia-Ying Sung, Kazue Ogawara, Takamichi Hattori.   

Abstract

Machado-Joseph disease is one of the most common hereditary spinocerebellar degenerative disorders with a wide range of clinical manifestations. Pathology studies have shown mild to moderate loss of anterior horn cells and, in terms of spinal pathology, Machado-Joseph disease is regarded as a type of lower motoneuron disease. Muscle cramps are often associated with lower motoneuron disorders, but features of cramps in Machado-Joseph disease patients have never been studied. We investigated the incidence and nature of muscle cramps in Machado-Joseph disease patients, the excitability properties of motor axons [strength-duration time constant (tau(SD)), threshold electrotonus, refractoriness and supernormality] using threshold tracking and the effects of mexiletine hydrochloride on those cramps. Of 20 consecutive patients, 16 (80%) had frequent, severe muscle cramps in the legs, trunk or arms that disturbed their daily activities. The frequency of pathological muscle cramps was similar to that for patients with amyotrophic lateral sclerosis (68%) and higher than those for patients with spinal muscular atrophy (33%) or peripheral axonal neuropathy (24%). Threshold-tracking studies showed that tau(SD), which in part reflects Na(+) conductance at the resting membrane potential, was significantly greater in the Machado-Joseph disease patients than in normal subjects; severe muscle cramps were associated with a longer tau(SD). Threshold electrotonus, refractoriness and supernormality were not significantly different between Machado-Joseph disease patients and normal subjects. Eight Machado-Joseph disease patients with severe cramps, who received mexiletine treatment, experienced nearly complete relief with a partial normalization of tau(SD) (P = 0.08). Muscle cramps are a very frequent and disabling factor in Machado-Joseph disease. Pathological muscle cramps responded well to mexiletine treatment, and this is consistent with the hypothesis that they are caused by an increase in persistent Na(+) conductance, possibly associated with axonal regeneration or collateral sprouting.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615652     DOI: 10.1093/brain/awg073

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  19 in total

1.  A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Authors:  Michael D Weiss; Eric A Macklin; Zachary Simmons; Angela S Knox; David J Greenblatt; Nazem Atassi; Michael Graves; Nicholas Parziale; Johnny S Salameh; Colin Quinn; Robert H Brown; Jane B Distad; Jaya Trivedi; Jeremy M Shefner; Richard J Barohn; Alan Pestronk; Andrea Swenson; Merit E Cudkowicz
Journal:  Neurology       Date:  2016-02-24       Impact factor: 9.910

Review 2.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

Review 3.  Current concepts in the treatment of hereditary ataxias.

Authors:  Pedro Braga Neto; José Luiz Pedroso; Sheng-Han Kuo; C França Marcondes Junior; Hélio Afonso Ghizoni Teive; Orlando Graziani Povoas Barsottini
Journal:  Arq Neuropsiquiatr       Date:  2016-03       Impact factor: 1.420

4.  Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.

Authors:  Björn Oskarsson; Dan Moore; Tahseen Mozaffar; John Ravits; Martina Wiedau-Pazos; Nicholas Parziale; Nanette C Joyce; Ross Mandeville; Namita Goyal; Merit E Cudkowicz; Michael Weiss; Robert G Miller; Craig M McDonald
Journal:  Muscle Nerve       Date:  2018-03-06       Impact factor: 3.217

Review 5.  Axonal Excitability in Amyotrophic Lateral Sclerosis : Axonal Excitability in ALS.

Authors:  Susanna B Park; Matthew C Kiernan; Steve Vucic
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

6.  Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease.

Authors:  Andreia Teixeira-Castro; Ana Jalles; Sofia Esteves; Soosung Kang; Liliana da Silva Santos; Anabela Silva-Fernandes; Mário F Neto; Renée M Brielmann; Carlos Bessa; Sara Duarte-Silva; Adriana Miranda; Stéphanie Oliveira; Andreia Neves-Carvalho; João Bessa; Teresa Summavielle; Richard B Silverman; Pedro Oliveira; Richard I Morimoto; Patrícia Maciel
Journal:  Brain       Date:  2015-09-15       Impact factor: 13.501

Review 7.  SCA3: neurological features, pathogenesis and animal models.

Authors:  Olaf Riess; Udo Rüb; Annalisa Pastore; Peter Bauer; Ludger Schöls
Journal:  Cerebellum       Date:  2008       Impact factor: 3.847

8.  Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial.

Authors:  Michael D Weiss; Eric A Macklin; Courtney E McIlduff; Steve Vucic; Brian J Wainger; Matthew C Kiernan; Stephen A Goutman; Namita A Goyal; Seward B Rutkove; Shafeeq S Ladha; I-Hweii Amy Chen; Matthew B Harms; Thomas H Brannagan; David Lacomis; Sasha Zivkovic; Maxwell Ma; Leo H Wang; Zachary Simmons; Michael H Rivner; Jeremy M Shefner; Merit E Cudkowicz; Nazem Atassi
Journal:  Muscle Nerve       Date:  2020-12-31       Impact factor: 3.217

9.  Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy.

Authors:  Michelle A Farrar; Steve Vucic; Cindy S-Y Lin; Susanna B Park; Heather M Johnston; Desirée du Sart; Hugh Bostock; Matthew C Kiernan
Journal:  Brain       Date:  2011-09-16       Impact factor: 13.501

10.  Strength-duration time constant in peripheral nerve: no abnormality in multiple sclerosis.

Authors:  Gençer Genç; Semai Bek; Tayfun Kasikci; Umit Hidir Ulas; Seref Demirkaya; Zeki Odabasi
Journal:  Mult Scler Int       Date:  2012-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.